Table 2.
Clinical characteristics of patients included in the study
| Characteristics | Value | |
|---|---|---|
| Patients from PALGA search | n = 14 | |
| Type of sample available | Pituitary tumor DNA, n = 13 (92.9%) | |
| Thyroid tumor DNA, n = 11 (78.6%) | ||
| Patients with known AIP germline variants | n = 3 | |
| Type of sample available | Pituitary tumor DNA, n = 2 (66.7%) | |
| Thyroid tumor DNA, n = 3 (100.0%) | ||
| Sex | Female/male: n = 15 (88.2%)/2 (11.8%) | |
| Age at onset pituitary adenoma (yrs) | Median, 51.5 (IQR 48.3–66.3) | |
| Age at onset thyroid carcinoma (yrs) | Median, 57.0 (IQR 44.0–69.0) | |
| No. and type of pituitary adenoma from available samples | Single, n = 12 (80.0%) | Multiple, n = 3 (20.0%) |
| Nonfunctioning, n = 5 (33.3%) | FSH + LH, n = 1 (6.7%) | |
| ACTH, n = 2 (15.0%) | FSH + TSH, n = 1 (6.7%) | |
| GH, n = 2 (15.0%) | GH + PRL, n = 1 (6.7%) | |
| LH, n = 1 (6.7%) | ||
| PRL, n = 1 (6.7%) | ||
| Unknown, n = 1 (6.7%) | ||
| No. and type of thyroid carcinoma from available samples | Single, n = 14 (100.0%) | |
| PTC, n = 7 (50.0%) | ||
| FTC, n = 4 (28.6%) | ||
| FVPTC, n = 3 (21.4%) | ||
| Metastasis | n = 5 (29.4%) | |
ACTH adrenocorticotropic hormone, FSH follicle-stimulating hormone, FTC follicular thyroid cancer, FVPTC follicular variant of papillary thyroid carcinoma, GH growth hormone, IQR interquartile range, LH luteinizing hormone, SS Sanger sequencing, TSH thyroid-stimulating hormone, PA pituitary adenoma, PRL prolactin, PTC papillary thyroid carcinoma, TC thyroid carcinoma, yrs years